A. S. Moubarak et al. / Agricultural Sciences 3 (2012) 795-798
Copyright © 2012 SciRes.
798
ET was different from that for ketoconazole in rat hepatic
CYP3A.
OPEN ACCESS
REFERENCES
[1] Porter, T.D. and Coon, M.J. (1991) Cytochrome P-450.
Multiplicity of isoforms, substrates, and catalytic and
regulatory mechanisms. Journal of Biological Chemistry,
266, 13469-13472.
[2] Brosen, K. (1993) The pharmacogenetics of the selective
serotonin reuptake inhibitors. Journal of Clinical Inves-
tigation, 71, 1002-1009.
[3] Pollock, B.G. (1994) Recent developments in drug me-
tabolism of relevance to psychiatrists. Harvard Review of
Psychiatry, 2, 204-213. doi:10.3109/10673229409017138
[4] DeVane, C.L. (1994) Pharmacokinetics of the newer an-
tidepressants: Clinical relevance. American Journal of
Medicine, 97, 13S-23S.
doi:10.1016/0002-9343(94)90359-X
[5] Wright, M.C. and Paine, A.J. (1994) Induction of the
cytochrome P450 3A subfamily in rat liver correlates with
the binding of inducers to a microsomal protein. Bio-
chemical and Biophysical Research Communications,
201, 973-979. doi:10.1006/bbrc.1994.1797
[6] Ball, S.E., Maurer, G., Zollinger, M., Ladona, M. and
Vickers, A.E. (1992) Characterization of the cytochrome
P-450 gene family responsible for the N-dealkylation of
the ergot alkaloid CQA 206-291 in humans. Drug Me-
tabolism and Disposition, 20, 56-63.
[7] Moochhala, S.M., Lee, E.J., Hu, G.T., Koh, O.S. and
Becket, G. (1989) Effects of bromocriptine on hepatic
cytochrome P-450 monooxygenase system. Japanese
Journal of Pharmacology, 49, 285-291.
doi:10.1254/jjp.49.285
[8] Thummel, K.E. and Wilkinson, G.R. (1998) In vitro and
in vivo drug interactions involving human CYP3A. An-
nual Review of Pharmacology and Toxicology, 38, 389-
430. doi:10.1146/annurev.pharmtox.38.1.389
[9] Witkamp, R.F., Nijmeijer, S.M., Monshouwer, M. and
Van Miert, A.S. (1995) The antibiotic tiamulin is a potent
inducer and inhibitor of cytochrome P4503A via the for-
mation of a stable metabolic intermediate complex. Stud-
ies in primary hepatocyte cultures and liver microsomes
of the pig. Drug Metabolism and Disposition, 23, 542-547.
[10] Lehmann, J.M., McKee, D.D., Watson, M.A., Willson,
T.M., Moore, J.T. and Kliewer, S.A. (1998) The human
orphan nuclear receptor PXR is activated by compounds
that regulate CYP3A4 gene expression and cause drug
interactions. Journal of Clinical Investigation, 102, 1016-
1102. doi:10.1172/JCI3703
[11] Moore, L.B., Parks, D.J., Jones, S.A., Bledsoe, R.K.,
Consler, T.G., Stimmel, J.B., Goodwin, B., Liddle, C.,
Blanchard, S.G., Willson, T.M., Collins, J.L. and Kliewer,
S.A. (2000) Orphan nuclear receptors constitutive andro-
stane receptor and pregnane X receptor share xenobiotic
and steroid ligands. Journal of Biological Chemistry, 275,
15122-15127. doi:10.1074/jbc.M001215200
[12] Sueyoshi, T., Kawamoto, T., Zelko, I., Honkakoski, P. and
Negishi, M. (1999) The repressed nuclear receptor CAR
responds to phenobarbital in activating the human
CYP2B6 gene. Journal of Biological Chemistry, 274,
6043-6046. doi:10.1074/jbc.274.10.6043
[13] Pascussi, J.M., Drocourt, L., Fabre, J.M., Maurel, P. and
Vilarem, M.J. (2000) Dexamethasone induces pregnane X
receptor and retinoid X receptor-alpha expression in hu-
man hepatocytes: Synergistic increase of CYP3A4 induc-
tion by pregnane X receptor activators. Molecular Phar-
macology, 58, 361-372. doi:10.1006/bbrc.2000.3219
[14] Honkakoski, P. and Negishi, M. (2000) Regulation of
cytochrome P450 (CYP) genes by nuclear receptors.
Biochemical Journal, 347, 321-337.
doi:10.1042/0264-6021:3470321
[15] Moubarak, A.S. and Rosenkrans Jr., C.F. (2000) Hepatic
metabolism of ergot alkaloids in beef cattle by cyto-
chrome P450. Biochem. Biochemical and Biophysical
Research Communications, 274, 746-749.
doi:10.1006/bbrc.2000.3210
[16] Lowry, O.H., Rosebrough, N.J., Farr, A.L. and Randall,
R.J.J. (1951) Protein measurements with folinphenol re-
agent. Biological Chemistry, 193, 265-275.
[17] Moubarak, A.S., Rosenkrans Jr., C.F. and Johnson, Z.B.
(2003) Modulation of cytochrome P450 metabolism by
ergonovine and dihydroergotamine. Veterinary & Human
Toxicology, 45, 6-9.
[18] Lampen, A., Christians, U., Guengerich, F.P., Watkins,
P.B., Kolars, J.C., Bader, A., Gonschior, A.K., Dralle, H.,
Hackbarth, I. and Sewing, K.F. (1995) Metabolism of the
immunosuppressant tacrolimus in the small intestine: cy-
tochrome P450, drug interactions, and interindividual
variability. Drug Metabolism and Disposition, 23, 1315-
1324.
[19] Christians, U., Schmidt, G., Bader, A., Lampen, A.,
Schottmann, R., Linck, A. and Sewing, K.F. (1996) Iden-
tification of drugs inhibiting the in vitro metabolism of
tacrolimus by human liver microsomes. British Journal of
Clinical Pharmacology, 41, 187-190.
doi:10.1111/j.1365-2125.1996.tb00181.x
[20] Althaus, M., Retzow, A., Castell, J.V., Gomez-Lechon,
M.J., Amalou, Z., Rose, T. and Appel, K. (2000) In vitro
identification of the cytochrome P450 isoform responsi-
ble for the metabolism of alpha-dihydroergocryptine. Xe-
nobiotica, 30, 1033-1045.
doi:10.1080/00498250010002261